Experimental evidence for proarrhythmic mechanisms of antiarrhythmic drugs

doi:10.1016/S0008-6363(97)00293-9

Cardiovascular Research 1998 37(3):567-577; doi:10.1016/S0008-6363(97)00293-9
© 1998 by European Society of Cardiology

This Article

	Full Text
	FREE Full Text (PDF)
	E-letters: Submit a response
	Alert me when this article is cited
	Alert me when E-letters are posted
	Alert me if a correction is posted

Services

	Email this article to a friend
	Similar articles in this journal
	Similar articles in PubMed
	Alert me to new issues of the journal
	Add to My Personal Archive
	Download to citation manager
	Request Permissions
	Disclaimer

Google Scholar

	Articles by Nattel, S.
	Search for Related Content

PubMed

	PubMed Citation
	Articles by Nattel, S.

Social Bookmarking

	What's this?

Experimental evidence for proarrhythmic mechanisms of antiarrhythmic drugs

Stanley Nattel^a^,b^,*

^aDepartment of Medicine, Montreal Heart Institute, 5000 Belanger Str. East, Montreal, Quebec H1T 1C8, Canada
^bUniversity of Montreal, Montreal, Quebec, Canada

^* Tel.: +1 (514) 376-3330; Fax: +1 (514) 376-1355.

The major limitation to antiarrhythmic drug therapy is the riskof arrhythmia promotion, or ‘proarrhythmia.’ Thiscomplication may be lethal, and greatly restricts the valueof antiarrhythmic agents, particularly for arrhythmias withoutan intrinsic mortality risk, such as atrial fibrillation. Inorder for improved antiarrhythmic drug therapy to be developed,it is essential to understand the fundamental mechanisms thatcause proarrhythmic reactions to antiarrhythmic drugs. The presentarticle reviews the experimental evidence that has been obtainedregarding the mechanisms of proarrhythmia. The evidence availableprovides important insights, and points to potential strategiesfor developing newer and safer antiarrhythmic compounds.

KEYWORDS Pharmacology; Ion channel blocker; Cardiac arrhythmia; Sodium channel blocker; Potassium channel blocker; Action potential duration; Early afterdepolarization; Ischemic heart disease

Add to CiteULike CiteULike Add to Connotea Connotea Add to Del.icio.us Del.icio.us What's this?

This article has been cited by other articles:

M. Sakabe, A. Shiroshita-Takeshita, A. Maguy, B. J.J.M. Brundel, A. Fujiki, H. Inoue, and S. Nattel
Effects of a heat shock protein inducer on the atrial fibrillation substrate caused by acute atrial ischaemia
Cardiovasc Res, April 1, 2008; 78(1): 63 - 70.
[Abstract] [Full Text] [PDF]

J. A. Vest, X. H.T. Wehrens, S. R. Reiken, S. E. Lehnart, D. Dobrev, P. Chandra, P. Danilo, U. Ravens, M. R. Rosen, and A. R. Marks
Defective Cardiac Ryanodine Receptor Regulation During Atrial Fibrillation
Circulation, April 26, 2005; 111(16): 2025 - 2032.
[Abstract] [Full Text] [PDF]

S. J. Canyon and G. P. Dobson
Protection against ventricular arrhythmias and cardiac death using adenosine and lidocaine during regional ischemia in the in vivo rat
Am J Physiol Heart Circ Physiol, September 1, 2004; 287(3): H1286 - H1295.
[Abstract] [Full Text] [PDF]

S. Nattel
Therapeutic implications of atrial fibrillation mechanisms: can mechanistic insights be used to improve AF management?
Cardiovasc Res, May 1, 2002; 54(2): 347 - 360.
[Abstract] [Full Text] [PDF]

J. A. Sánchez-Chapula, E. Salinas-Stefanon, J. Torres-Jácome, D. E. Benavides-Haro, and R. A. Navarro-Polanco
Blockade of Currents by the Antimalarial Drug Chloroquine in Feline Ventricular Myocytes
J. Pharmacol. Exp. Ther., April 1, 2001; 297(1): 437 - 445.
[Abstract] [Full Text]

A. Benardeau, S. Fareh, and S. Nattel
Effects of verapamil on atrial fibrillation and its electrophysiological determinants in dogs
Cardiovasc Res, April 1, 2001; 50(1): 85 - 96.
[Abstract] [Full Text] [PDF]

P. Dorian and D. Newman
Rate dependence of the effect of antiarrhythmic drugs delaying cardiac repolarization: an overview
Europace, January 1, 2000; 2(4): 277 - 285.
[Abstract] [PDF]

				J. A. Vest, X. H.T. Wehrens, S. R. Reiken, S. E. Lehnart, D. Dobrev, P. Chandra, P. Danilo, U. Ravens, M. R. Rosen, and A. R. Marks Defective Cardiac Ryanodine Receptor Regulation During Atrial Fibrillation Circulation, April 26, 2005; 111(16): 2025 - 2032. [Abstract] [Full Text] [PDF]

				S. J. Canyon and G. P. Dobson Protection against ventricular arrhythmias and cardiac death using adenosine and lidocaine during regional ischemia in the in vivo rat Am J Physiol Heart Circ Physiol, September 1, 2004; 287(3): H1286 - H1295. [Abstract] [Full Text] [PDF]

				S. Nattel Therapeutic implications of atrial fibrillation mechanisms: can mechanistic insights be used to improve AF management? Cardiovasc Res, May 1, 2002; 54(2): 347 - 360. [Abstract] [Full Text] [PDF]

				J. A. Sánchez-Chapula, E. Salinas-Stefanon, J. Torres-Jácome, D. E. Benavides-Haro, and R. A. Navarro-Polanco Blockade of Currents by the Antimalarial Drug Chloroquine in Feline Ventricular Myocytes J. Pharmacol. Exp. Ther., April 1, 2001; 297(1): 437 - 445. [Abstract] [Full Text]

				A. Benardeau, S. Fareh, and S. Nattel Effects of verapamil on atrial fibrillation and its electrophysiological determinants in dogs Cardiovasc Res, April 1, 2001; 50(1): 85 - 96. [Abstract] [Full Text] [PDF]

				P. Dorian and D. Newman Rate dependence of the effect of antiarrhythmic drugs delaying cardiac repolarization: an overview Europace, January 1, 2000; 2(4): 277 - 285. [Abstract] [PDF]